Drugs / Rilvegostomig Alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07847710 | Sep 2026 → Mar 2028 expected | intrahepatic cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rilvegostomig Alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07847710 ↗ |
| Action | Inhibit | “Anti-PD-L1” NCT07847710 ↗ |
| Modality | Protein / enzyme biologic | “Anti-PD-L1/TGF-β Bifunctional Fusion Protein” NCT07847710 ↗ |
| Route | Intravenous | “30 mg/kg, i.v., q3w, Day 1 of each 3-week cycle.” NCT07847710 ↗ |